AMRI Awarded Development and Manufacture Contract from the UK Government
ALBANY, New York, Sept. 30, 2013
ALBANY, New York, Sept. 30, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today
announced that its wholly owned subsidiary, Albany Molecular Research (UK)
Ltd., located in Holywell, Wales, United Kingdom, has been awarded a
seven-year contract for the development and manufacture of an active
ingredient under clinical evaluation. The contract was awarded by the Defense
Science and Technology Laboratory (Dstl), acting on behalf of the United
Kingdom's Secretary of State for Defence, the Department of National Defence
of Canada and Minister of Defence of the Kingdom of the Netherlands.
AMRI will initially work on the development and scale-up of the
investigational drug, and subsequently the manufacture and supply for use
during phase 1 clinical trials. If the trials are successful, AMRI will be in
a strong position to become the commercial manufacturer of the product for
distribution to the government partners of this contract including the United
Kingdom, Netherlands and Canada.
"We are excited for the opportunity to work on this important project for the
UK government," said AMRI's President and CEO, Thomas E. D'Ambra, Ph.D.
"Government contracts and related collaborations outside of our typical
outsourcing contracts with biotechnology and pharmaceutical companies are part
of our strategy to diversify our revenue base while making our high-quality
services available to all industries, sectors and organizations that can
benefit from our strengths in discovery, development and manufacturing."
This collaboration underscores AMRI's expertise in providing SMARTSOURCING™
solutions to government agencies working to solve critical health issues. This
includes work as both a contractor and subcontractor for various agencies of
the U.S. government. AMRI has been a subcontractor in the manufacturing arena
for the U.S. Department of Defense for more than a decade. In August 2011,
AMRI received a federal contract award from the National Institutes of Health
(NIH) / National Institute of Neurological Disorders and Stroke (NINDS) to
provide chemistry and other drug discovery technologies in support of NINDS'
Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH
Blueprint Neurotherapeutics Network (BPN). This five-year contract provides
AMRI with funding of up to $43 million, based on the number of approved
projects and availability of funds.
About AMRI Albany Molecular Research, Inc. (AMRI) is a global contract
research and manufacturing organization offering customers fully integrated
drug discovery, development and manufacturing services. For over 21 years,
AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING
^™ , a full range of value-added opportunities providing customers with
informed decision-making, enhanced efficiency and more successful outcomes at
all stages of the pipeline. AMRI has also successfully partnered R&D programs
and is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at
http://www.amriglobal.com/ or follow us on Twitter ( @amriglobal ).
About Albany Molecular Research (UK) Ltd. Albany Molecular Research (UK) Ltd.,
a wholly owned subsidiary of AMRI, provides development and manufacturing
services, including pre-clinical and Phase I – III product development, as
well as commercial manufacturing for approved products. The 14-acre site is
located about 60 miles outside of Manchester, England and contains Kilo lab,
pilot plant and large-scale manufacturing capabilities. In 2012, the site
received a Good Manufacturing Practice (GMP) certificate from the Medicines
and Healthcare Regulatory Agency (MHRA) of the UK government for AMRI's
manufacturing facility in Holywell, Wales, UK, underscoring the quality of the
facility and its growth potential.
Contact: Investors, Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261, Media, Gina Monari, AMRI Communications, +1-518-512-2512
Press spacebar to pause and continue. Press esc to stop.